Clinical Trial Update: Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML [Phase 3]

View source ↗

Summary

Phase 3 trial investigating entospletinib plus intensive induction/consolidation chemotherapy in newly diagnosed NPM1-mutated AML has been terminated; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nucleophosmin 1-mutated Acute Myeloid Leukemia

Drugs mentioned

• Entospletinib (entospletinib)

Snippet

Sponsor: Kronos Bio | Conditions: Nucleophosmin 1-mutated Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2024-01-10